1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Standard 1.2.3 Exellent 1.3 Market by Application 1.3.1 Global Non Hodgkin Lymphoma (NHL) Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hosptial 1.3.3 Clinic 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Non Hodgkin Lymphoma (NHL) Market Perspective (2017-2028) 2.2 Non Hodgkin Lymphoma (NHL) Growth Trends by Region 2.2.1 Non Hodgkin Lymphoma (NHL) Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Non Hodgkin Lymphoma (NHL) Historic Market Size by Region (2017-2022) 2.2.3 Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Region (2023-2028) 2.3 Non Hodgkin Lymphoma (NHL) Market Dynamics 2.3.1 Non Hodgkin Lymphoma (NHL) Industry Trends 2.3.2 Non Hodgkin Lymphoma (NHL) Market Drivers 2.3.3 Non Hodgkin Lymphoma (NHL) Market Challenges 2.3.4 Non Hodgkin Lymphoma (NHL) Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Non Hodgkin Lymphoma (NHL) Players by Revenue 3.1.1 Global Top Non Hodgkin Lymphoma (NHL) Players by Revenue (2017-2022) 3.1.2 Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Players (2017-2022) 3.2 Global Non Hodgkin Lymphoma (NHL) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Non Hodgkin Lymphoma (NHL) Revenue 3.4 Global Non Hodgkin Lymphoma (NHL) Market Concentration Ratio 3.4.1 Global Non Hodgkin Lymphoma (NHL) Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Non Hodgkin Lymphoma (NHL) Revenue in 2021 3.5 Non Hodgkin Lymphoma (NHL) Key Players Head office and Area Served 3.6 Key Players Non Hodgkin Lymphoma (NHL) Product Solution and Service 3.7 Date of Enter into Non Hodgkin Lymphoma (NHL) Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Non Hodgkin Lymphoma (NHL) Breakdown Data by Type 4.1 Global Non Hodgkin Lymphoma (NHL) Historic Market Size by Type (2017-2022) 4.2 Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Type (2023-2028) 5 Non Hodgkin Lymphoma (NHL) Breakdown Data by Application 5.1 Global Non Hodgkin Lymphoma (NHL) Historic Market Size by Application (2017-2022) 5.2 Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Non Hodgkin Lymphoma (NHL) Market Size (2017-2028) 6.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) 6.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Non Hodgkin Lymphoma (NHL) Market Size (2017-2028) 7.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) 7.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size (2017-2028) 8.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) 8.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Non Hodgkin Lymphoma (NHL) Market Size (2017-2028) 9.2 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) 9.3 Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size (2017-2028) 10.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) 10.3 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 F. Hoffmann-La Roche 11.1.1 F. Hoffmann-La Roche Company Detail 11.1.2 F. Hoffmann-La Roche Business Overview 11.1.3 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Introduction 11.1.4 F. Hoffmann-La Roche Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.1.5 F. Hoffmann-La Roche Recent Development 11.2 Johnson & Johnson 11.2.1 Johnson & Johnson Company Detail 11.2.2 Johnson & Johnson Business Overview 11.2.3 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Introduction 11.2.4 Johnson & Johnson Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.2.5 Johnson & Johnson Recent Development 11.3 Merck 11.3.1 Merck Company Detail 11.3.2 Merck Business Overview 11.3.3 Merck Non Hodgkin Lymphoma (NHL) Introduction 11.3.4 Merck Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.3.5 Merck Recent Development 11.4 Bristol Myers Squibb 11.4.1 Bristol Myers Squibb Company Detail 11.4.2 Bristol Myers Squibb Business Overview 11.4.3 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Introduction 11.4.4 Bristol Myers Squibb Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.4.5 Bristol Myers Squibb Recent Development 11.5 Celgene 11.5.1 Celgene Company Detail 11.5.2 Celgene Business Overview 11.5.3 Celgene Non Hodgkin Lymphoma (NHL) Introduction 11.5.4 Celgene Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.5.5 Celgene Recent Development 11.6 Eli Lilly 11.6.1 Eli Lilly Company Detail 11.6.2 Eli Lilly Business Overview 11.6.3 Eli Lilly Non Hodgkin Lymphoma (NHL) Introduction 11.6.4 Eli Lilly Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.6.5 Eli Lilly Recent Development 11.7 GlaxoSmithKline 11.7.1 GlaxoSmithKline Company Detail 11.7.2 GlaxoSmithKline Business Overview 11.7.3 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Introduction 11.7.4 GlaxoSmithKline Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.7.5 GlaxoSmithKline Recent Development 11.8 Bayer 11.8.1 Bayer Company Detail 11.8.2 Bayer Business Overview 11.8.3 Bayer Non Hodgkin Lymphoma (NHL) Introduction 11.8.4 Bayer Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) 11.8.5 Bayer Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Standard Table 3. Key Players of Exellent Table 4. Global Non Hodgkin Lymphoma (NHL) Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 5. Global Non Hodgkin Lymphoma (NHL) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 6. Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2017-2022) & (US$ Million) Table 7. Global Non Hodgkin Lymphoma (NHL) Market Share by Region (2017-2022) Table 8. Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 9. Global Non Hodgkin Lymphoma (NHL) Market Share by Region (2023-2028) Table 10. Non Hodgkin Lymphoma (NHL) Market Trends Table 11. Non Hodgkin Lymphoma (NHL) Market Drivers Table 12. Non Hodgkin Lymphoma (NHL) Market Challenges Table 13. Non Hodgkin Lymphoma (NHL) Market Restraints Table 14. Global Non Hodgkin Lymphoma (NHL) Revenue by Players (2017-2022) & (US$ Million) Table 15. Global Non Hodgkin Lymphoma (NHL) Market Share by Players (2017-2022) Table 16. Global Top Non Hodgkin Lymphoma (NHL) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non Hodgkin Lymphoma (NHL) as of 2021) Table 17. Ranking of Global Top Non Hodgkin Lymphoma (NHL) Companies by Revenue (US$ Million) in 2021 Table 18. Global 5 Largest Players Market Share by Non Hodgkin Lymphoma (NHL) Revenue (CR5 and HHI) & (2017-2022) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Non Hodgkin Lymphoma (NHL) Product Solution and Service Table 21. Date of Enter into Non Hodgkin Lymphoma (NHL) Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2017-2022) & (US$ Million) Table 24. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2017-2022) Table 25. Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 26. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2023-2028) Table 27. Global Non Hodgkin Lymphoma (NHL) Market Size by Application (2017-2022) & (US$ Million) Table 28. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2017-2022) Table 29. Global Non Hodgkin Lymphoma (NHL) Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 30. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2023-2028) Table 31. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) & (US$ Million) Table 32. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) & (US$ Million) Table 33. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) & (US$ Million) Table 34. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) & (US$ Million) Table 35. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2017-2022) & (US$ Million) Table 36. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Region (2023-2028) & (US$ Million) Table 37. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) & (US$ Million) Table 38. Latin America Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) & (US$ Million) Table 39. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2017-2022) & (US$ Million) Table 40. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2023-2028) & (US$ Million) Table 41. F. Hoffmann-La Roche Company Detail Table 42. F. Hoffmann-La Roche Business Overview Table 43. F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product Table 44. F. Hoffmann-La Roche Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 45. F. Hoffmann-La Roche Recent Development Table 46. Johnson & Johnson Company Detail Table 47. Johnson & Johnson Business Overview Table 48. Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product Table 49. Johnson & Johnson Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 50. Johnson & Johnson Recent Development Table 51. Merck Company Detail Table 52. Merck Business Overview Table 53. Merck Non Hodgkin Lymphoma (NHL) Product Table 54. Merck Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 55. Merck Recent Development Table 56. Bristol Myers Squibb Company Detail Table 57. Bristol Myers Squibb Business Overview Table 58. Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product Table 59. Bristol Myers Squibb Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 60. Bristol Myers Squibb Recent Development Table 61. Celgene Company Detail Table 62. Celgene Business Overview Table 63. Celgene Non Hodgkin Lymphoma (NHL) Product Table 64. Celgene Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 65. Celgene Recent Development Table 66. Eli Lilly Company Detail Table 67. Eli Lilly Business Overview Table 68. Eli Lilly Non Hodgkin Lymphoma (NHL) Product Table 69. Eli Lilly Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 70. Eli Lilly Recent Development Table 71. GlaxoSmithKline Company Detail Table 72. GlaxoSmithKline Business Overview Table 73. GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product Table 74. GlaxoSmithKline Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 75. GlaxoSmithKline Recent Development Table 76. Bayer Company Detail Table 77. Bayer Business Overview Table 78. Bayer Non Hodgkin Lymphoma (NHL) Product Table 79. Bayer Revenue in Non Hodgkin Lymphoma (NHL) Business (2017-2022) & (US$ Million) Table 80. Bayer Recent Development Table 81. Research Programs/Design for This Report Table 82. Key Data Information from Secondary Sources Table 83. Key Data Information from Primary Sources List of Figures Figure 1. Global Non Hodgkin Lymphoma (NHL) Market Share by Type: 2021 VS 2028 Figure 2. Standard Features Figure 3. Exellent Features Figure 4. Global Non Hodgkin Lymphoma (NHL) Market Share by Application in 2021 & 2028 Figure 5. Hosptial Case Studies Figure 6. Clinic Case Studies Figure 7. Non Hodgkin Lymphoma (NHL) Report Years Considered Figure 8. Global Non Hodgkin Lymphoma (NHL) Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 9. Global Non Hodgkin Lymphoma (NHL) Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 10. Global Non Hodgkin Lymphoma (NHL) Market Share by Region: 2021 VS 2028 Figure 11. Global Non Hodgkin Lymphoma (NHL) Market Share by Players in 2021 Figure 12. Global Top Non Hodgkin Lymphoma (NHL) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non Hodgkin Lymphoma (NHL) as of 2021) Figure 13. The Top 10 and 5 Players Market Share by Non Hodgkin Lymphoma (NHL) Revenue in 2021 Figure 14. North America Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 15. North America Non Hodgkin Lymphoma (NHL) Market Share by Country (2017-2028) Figure 16. United States Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 17. Canada Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 18. Europe Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. Europe Non Hodgkin Lymphoma (NHL) Market Share by Country (2017-2028) Figure 20. Germany Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. France Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. U.K. Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Italy Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Russia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Nordic Countries Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Share by Region (2017-2028) Figure 28. China Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Japan Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. South Korea Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Southeast Asia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. India Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Australia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Latin America Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Latin America Non Hodgkin Lymphoma (NHL) Market Share by Country (2017-2028) Figure 36. Mexico Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Brazil Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Country (2017-2028) Figure 40. Turkey Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Saudi Arabia Non Hodgkin Lymphoma (NHL) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. F. Hoffmann-La Roche Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 43. Johnson & Johnson Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 44. Merck Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 45. Bristol Myers Squibb Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 46. Celgene Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 47. Eli Lilly Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 48. GlaxoSmithKline Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 49. Bayer Revenue Growth Rate in Non Hodgkin Lymphoma (NHL) Business (2017-2022) Figure 50. Bottom-up and Top-down Approaches for This Report Figure 51. Data Triangulation Figure 52. Key Executives Interviewed

F. Hoffmann-La Roche Johnson & Johnson Merck Bristol Myers Squibb Celgene Eli Lilly GlaxoSmithKline Bayer